Mallinckrodt files NDA for Optimark

Article

Mallinckrodt has filed a new drug application for its Optimark MRI contrast agent, the St. Louis company announced this month. Optimark (Gd-DTPA-BMEA) is an extracellular agent designed for visualizing lesions in the brain, spine, and liver. Mallinckrodt

Mallinckrodt has filed a new drug application for its Optimark MRI contrast agent, the St. Louis company announced this month. Optimark (Gd-DTPA-BMEA) is an extracellular agent designed for visualizing lesions in the brain, spine, and liver. Mallinckrodt developed the product internally.

Optimark's approval will be an important milestone for Mallinckrodt, rounding out its product portfolio and making it easier for the company to win single-source supply deals with large purchasers. Mallinckrodt's product line already includes agents for x-ray, ultrasound, and CT, as well as organ-specific MRI studies, but the firm does not offer contrast media for MRI scans in the central nervous system, which composes the lion's share of MRI studies. Optimark will compete with general-purpose MRI agents such as Schering's Magnevist, Bracco's ProHance, and Nycomed Amersham's Omniscan.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.